United States Biotechnology & Medical Research

LENZ Therapeutics Inc (LENZ)

Track

LENZ Therapeutics Inc. saw its most recent insider activity on March 27, 2026, when key executives, including the CEO and CFO, executed multiple share purchases. These acquisitions follow a period of varied divestment patterns by other stakeholders during late 2025. No trading has occurred within the last three months.
Ticker: LENZ Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for LENZ Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.4
George Jeffrey P. Non-Executive Director
Transaction date
Purchase
Price
413.96
Quantity 32,450 -28.5%
Value US$1,843,122
3.0
Chevallard Daniel R. Chief Financial Officer Officer
Transaction date
Purchase
Price
194.68
Quantity 46,083 -1.8%
Value US$3,299,856
1.4
Schimmelpennink Evert B. President, CEO and Secretary Executive Director
Transaction date
Purchase
Price
470.55
Quantity 20,141 -36.0%
Value US$4,713,244
Olsson Shawn Chief Commercial Officer Officer
Transaction date
Planned sale
Price
26.37
Quantity 5,788 -55.0%
Value US$152,612
Olsson Shawn Chief Commercial Officer Officer
Transaction date
Planned sale
Price
25.74
Quantity 4,212 -28.6%
Value US$108,411
SHAWN OLSSON Officer Officer
Transaction date
Proposed sale
Price
25.60
Quantity 40,000
Value US$1,024,000
3.4
MCCOLLUM JAMES W Non-Executive Director
Transaction date
Purchase
Price
22.79
Quantity 10,500 +inf%
Value US$239,278
3.0
Chevallard Daniel R. Chief Financial Officer Officer
Transaction date
Purchase
Price
22.76
Quantity 2,178 +67.9%
Value US$49,563
3.0
Chevallard Daniel R. Chief Financial Officer Officer
Transaction date
Purchase
Price
22.71
Quantity 20 +0.6%
Value US$454
3.0
Chevallard Daniel R. Chief Financial Officer Officer
Transaction date
Purchase
Price
15.68
Quantity 3,188 +inf%
Value US$49,988
3.0
Chevallard Daniel R. Chief Financial Officer Officer
Transaction date
Purchase
Price
15.68
Quantity 3,188 +inf%
Value US$49,988
3.4
MCCOLLUM JAMES W Non-Executive Director
Transaction date
Purchase
Price
15.99
Quantity 31,332 +6.3%
Value US$501,093
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
15.03
Quantity 64,971 +10.3%
Value US$976,514
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
15.03
Quantity 933,038 +39.1%
Value US$14,023,561
1.7
Samsara BioCapital, L.P. Large shareholder
Transaction date
Purchase
Price
4.08
Quantity 350,000 +4.3%
Value US$1,428,000
Gutry Phil CHIEF BUSINESS OFFICER Officer
Transaction date
Planned purchase
Price
4.01
Quantity 5,000 +1.7%
Value US$20,050
1.7
Samsara BioCapital, L.P. Large shareholder
Transaction date
Purchase
Price
8.99
Quantity 100,000 +1.3%
Value US$899,000
1.7
Samsara BioCapital, L.P. Large shareholder
Transaction date
Purchase
Price
10.19
Quantity 22,329 +0.3%
Value US$227,533
1.7
Samsara BioCapital, L.P. Large shareholder
Transaction date
Purchase
Price
10.15
Quantity 201,685 +2.7%
Value US$2,047,103
1.7
Samsara BioCapital, L.P. Large shareholder
Transaction date
Purchase
Price
13.22
Quantity 45,400 +0.6%
Value US$600,188
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-30 2026-03-27 B Purchase
2.4
George Jeffrey P.
Non-Executive Director
32,450 -28.5%
413.96
US$1,843,122 		32,450 -28.5% 413.96 US$1,843,122
2026-03-30 2026-03-27 B Purchase
3.0
Chevallard Daniel R.

Chief Financial Officer

Officer
46,083 -1.8%
194.68
US$3,299,856 		46,083 -1.8% 194.68 US$3,299,856
2026-03-30 2026-03-27 B Purchase
1.4
Schimmelpennink Evert B.

President, CEO and Secretary

Executive Director
20,141 -36.0%
470.55
US$4,713,244 		20,141 -36.0% 470.55 US$4,713,244
2025-11-19 2025-11-17 PlS Planned sale
Olsson Shawn

Chief Commercial Officer

Officer
5,788 -55.0%
26.37
US$152,612 		5,788 -55.0% 26.37 US$152,612
2025-11-19 2025-11-17 PlS Planned sale
Olsson Shawn

Chief Commercial Officer

Officer
4,212 -28.6%
25.74
US$108,411 		4,212 -28.6% 25.74 US$108,411
2025-11-17 2025-11-17 PrS Proposed sale
SHAWN OLSSON

Officer

Officer
40,000
25.60
US$1,024,000 		40,000 25.60 US$1,024,000
2025-11-10 2025-11-07 B Purchase
3.4
MCCOLLUM JAMES W
Non-Executive Director
10,500 +inf%
22.79
US$239,278 		10,500 +inf% 22.79 US$239,278
2025-11-07 2025-11-07 B Purchase
3.0
Chevallard Daniel R.

Chief Financial Officer

Officer
2,178 +67.9%
22.76
US$49,563 		2,178 +67.9% 22.76 US$49,563
2025-11-07 2025-11-07 B Purchase
3.0
Chevallard Daniel R.

Chief Financial Officer

Officer
20 +0.6%
22.71
US$454 		20 +0.6% 22.71 US$454
2025-10-02 2025-09-30 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
123 -0.0%
47.01
US$5,783 		123 -0.0% 47.01 US$5,783
2025-10-02 2025-09-30 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
177 -0.0%
47.01
US$8,321 		177 -0.0% 47.01 US$8,321
2025-10-02 2025-09-30 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
57,502 -7.0%
46.41
US$2,668,484 		57,502 -7.0% 46.41 US$2,668,484
2025-10-02 2025-09-30 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
83,066 -7.3%
46.41
US$3,854,827 		83,066 -7.3% 46.41 US$3,854,827
2025-10-02 2025-09-30 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
34,405 -4.0%
45.35
US$1,560,428 		34,405 -4.0% 45.35 US$1,560,428
2025-10-02 2025-09-30 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
49,701 -4.2%
45.35
US$2,254,174 		49,701 -4.2% 45.35 US$2,254,174
2025-09-22 2025-09-18 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
132 -0.0%
43.30
US$5,716 		132 -0.0% 43.30 US$5,716
2025-09-22 2025-09-18 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
268 -0.0%
43.30
US$11,604 		268 -0.0% 43.30 US$11,604
2025-09-22 2025-09-18 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
20,148 -2.3%
43.00
US$866,441 		20,148 -2.3% 43.00 US$866,441
2025-09-22 2025-09-18 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
40,907 -3.3%
43.00
US$1,759,156 		40,907 -3.3% 43.00 US$1,759,156
2025-09-22 2025-09-18 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
24,370 -2.7%
41.59
US$1,013,568 		24,370 -2.7% 41.59 US$1,013,568
2025-09-22 2025-09-18 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
49,479 -3.9%
41.59
US$2,057,871 		49,479 -3.9% 41.59 US$2,057,871
2025-08-26 2025-08-26 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
1,707 -0.2%
39.50
US$67,430 		1,707 -0.2% 39.50 US$67,430
2025-08-26 2025-08-26 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
3,465 -0.3%
39.50
US$136,875 		3,465 -0.3% 39.50 US$136,875
2025-08-26 2025-08-26 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
21,661 -2.3%
38.97
US$844,224 		21,661 -2.3% 38.97 US$844,224
2025-08-26 2025-08-26 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
43,978 -3.3%
38.97
US$1,714,016 		43,978 -3.3% 38.97 US$1,714,016
2025-08-26 2025-08-25 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
1,058 -0.1%
39.92
US$42,237 		1,058 -0.1% 39.92 US$42,237
2025-08-26 2025-08-25 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
2,149 -0.2%
39.92
US$85,791 		2,149 -0.2% 39.92 US$85,791
2025-08-26 2025-08-25 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
24,760 -2.6%
39.53
US$978,651 		24,760 -2.6% 39.53 US$978,651
2025-08-26 2025-08-25 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
50,270 -3.7%
39.53
US$1,986,947 		50,270 -3.7% 39.53 US$1,986,947
2025-08-26 2025-08-22 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
2,809 -0.3%
40.59
US$114,017 		2,809 -0.3% 40.59 US$114,017
2025-08-26 2025-08-22 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
5,668 -0.4%
40.59
US$230,064 		5,668 -0.4% 40.59 US$230,064
2025-08-26 2025-08-22 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
10,076 -1.0%
40.03
US$403,339 		10,076 -1.0% 40.03 US$403,339
2025-08-26 2025-08-22 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
20,493 -1.5%
40.03
US$820,329 		20,493 -1.5% 40.03 US$820,329
2025-08-19 2025-08-18 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
15,085 -1.5%
38.56
US$581,694 		15,085 -1.5% 38.56 US$581,694
2025-08-19 2025-08-18 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
30,628 -2.1%
38.56
US$1,181,049 		30,628 -2.1% 38.56 US$1,181,049
2025-08-19 2025-08-15 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
69,949 -6.7%
39.50
US$2,762,986 		69,949 -6.7% 39.50 US$2,762,986
2025-08-19 2025-08-15 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
145,051 -9.2%
39.50
US$5,729,514 		145,051 -9.2% 39.50 US$5,729,514
2025-07-14 2025-07-10 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
191,376 -10.8%
34.00
US$6,506,784 		191,376 -10.8% 34.00 US$6,506,784
2025-07-01 2025-06-27 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
200,000 -10.2%
30.47
US$6,093,000 		200,000 -10.2% 30.47 US$6,093,000
2025-06-20 2025-06-20 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
133,924 -6.4%
30.25
US$4,051,201 		133,924 -6.4% 30.25 US$4,051,201
2025-06-20 2025-06-20 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
100,877 -8.8%
30.35
US$3,061,617 		100,877 -8.8% 30.35 US$3,061,617
2025-06-20 2025-06-18 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
100,000 -8.0%
29.95
US$2,995,000 		100,000 -8.0% 29.95 US$2,995,000
2025-06-12 2025-06-10 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
350,000 -21.9%
29.00
US$10,150,000 		350,000 -21.9% 29.00 US$10,150,000
2024-05-15 2024-05-14 B Purchase
3.0
Chevallard Daniel R.

Chief Financial Officer

Officer
3,188 +inf%
15.68
US$49,988 		3,188 +inf% 15.68 US$49,988
2024-05-15 2024-05-14 B Purchase
3.0
Chevallard Daniel R.

Chief Financial Officer

Officer
3,188 +inf%
15.68
US$49,988 		3,188 +inf% 15.68 US$49,988
2024-05-14 2024-05-13 B Purchase
3.4
MCCOLLUM JAMES W
Non-Executive Director
31,332 +6.3%
15.99
US$501,093 		31,332 +6.3% 15.99 US$501,093
2024-03-25 2024-03-21 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
64,971 +10.3%
15.03
US$976,514 		64,971 +10.3% 15.03 US$976,514
2024-03-25 2024-03-21 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
933,038 +39.1%
15.03
US$14,023,561 		933,038 +39.1% 15.03 US$14,023,561
2022-04-13 2022-04-12 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
350,000 +4.3%
4.08
US$1,428,000 		350,000 +4.3% 4.08 US$1,428,000
2022-04-13 2022-04-11 PP Planned purchase
Gutry Phil

CHIEF BUSINESS OFFICER

Officer
5,000 +1.7%
4.01
US$20,050 		5,000 +1.7% 4.01 US$20,050
2022-04-13 2022-04-11 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
74,464 +0.9%
4.07
US$303,068 		74,464 +0.9% 4.07 US$303,068
2022-01-25 2022-01-24 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
23,000 +0.3%
8.70
US$200,100 		23,000 +0.3% 8.70 US$200,100
2022-01-25 2022-01-21 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
100,000 +1.3%
8.99
US$899,000 		100,000 +1.3% 8.99 US$899,000
2022-01-21 2022-01-20 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
43,105 +0.5%
8.92
US$384,497 		43,105 +0.5% 8.92 US$384,497
2022-01-21 2022-01-19 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
54,565 +0.7%
9.24
US$504,181 		54,565 +0.7% 9.24 US$504,181
2021-12-20 2021-12-15 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
22,329 +0.3%
10.19
US$227,533 		22,329 +0.3% 10.19 US$227,533
2021-11-24 2021-11-22 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
201,685 +2.7%
10.15
US$2,047,103 		201,685 +2.7% 10.15 US$2,047,103
2021-10-15 2021-10-15 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
2,300 +0.0%
12.49
US$28,727 		2,300 +0.0% 12.49 US$28,727
2021-10-15 2021-10-14 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
3,100 +0.0%
12.50
US$38,750 		3,100 +0.0% 12.50 US$38,750
2021-10-15 2021-10-13 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
45,400 +0.6%
13.22
US$600,188 		45,400 +0.6% 13.22 US$600,188
2021-10-08 2021-10-08 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
75,000 +1.0%
13.12
US$984,000 		75,000 +1.0% 13.12 US$984,000
2021-10-08 2021-10-07 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
9,021 +0.1%
14.94
US$134,774 		9,021 +0.1% 14.94 US$134,774
2021-10-08 2021-10-06 B Purchase
1.7
Samsara BioCapital, L.P.
Large shareholder
61,475 +0.8%
13.83
US$850,199 		61,475 +0.8% 13.83 US$850,199
Explore more

More insider trading research around LENZ Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America